Welcome Center  |   Log In  |   Register  |   Follow Us  Facebook  Twitter

Avoiding Complications During the Initiation of Treatment of Diabetes

Best Practice Series in Diabetes - Type 2

Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, reviews the initiation of therapy for Type 2 Diabetes and how to best avoid complications and side effects.

Disclosures:
Speaker’s Bureau: Merck, NovoNordisk, GSK
Advisory Panel: Merck, BMS, Astra Zeneca, Boehringer Ingelheim, Biodel
Consultant: Merck, Novartis, Dainippon Sumitomo Pharma America, Forest Laboratories
Stock/Shareholder: Covidien, Bard, Novartis, Roche, Stryker

References:
Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Bergenstal RM, Bailey CJ, Kendall DM. Am J Med. 2010 Apr;123(4):374.e 9 -18. Review.

Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Nissen SE, Wolski K.